Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis

王晓澍; 游潮; 孙晓川

您当前的位置：

首页 >

文章列表页 >

Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis

更新时间：2026-01-09

- Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis
- Journal of Army Medical University Vol. 32, Issue 9, Pages: 985-988(2010)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R341;R730.23;R730.264
- Published：2010
- 稿件说明：
移动端阅览
王晓澍,游潮,孙晓川.MCT1、CD147在人胶质瘤中的表达、相关性及其与预后的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(09):985-988.

　Wang Xiaoshu,You Chao,Sun Xiaochuan.Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(09):985-988.
王晓澍,游潮,孙晓川.MCT1、CD147在人胶质瘤中的表达、相关性及其与预后的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(09):985-988. DOI：

　Wang Xiaoshu,You Chao,Sun Xiaochuan.Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(09):985-988. DOI：

摘要

目的探讨单羧酸转运蛋白-1（monocarboxylate transporter-1

MCT1）和CD147在不同级别人脑胶质瘤中的表达情况及其与胶质瘤预后的关系。方法采用免疫组化SP法检测MCT1和CD147在28例低级别胶质瘤和32例高级别胶质瘤中的表达情况；建立前瞻性队列随访观察上述胶质瘤患者术后情况，使用生存曲线和COX多因素模型进行生存预后分析。结果 MCT1和CD147在人脑胶质瘤中均有高表达；在高级别胶质瘤中，两者的阳性表达率（93.8%、90.6%）和强阳性表达率（73.3%、72.4%）显著高于低级别组(两者的阳性表达率为46.4%、50%，强阳性表达率为30.8%、35.7%，P0.01，P0.05)，且两者表达呈正相关(r=0.671，P0.05)；MCT1和CD147表达相关生存曲线差异有统计学意义（P=0.021，P=0.001），COX分析CD147高表达对胶质瘤患者的术后生存预后具有明显影响（P=0.017）。结论 MCT1和CD147与胶质瘤恶性程度有密切关系，两者的表达，尤其是CD147可作为胶质瘤预后判断的参考指标和治疗靶点。

Abstract

Objective To investigate the expressions and correlation of monocarboxylate transporter-1 (MCT1) and CD147 in human gliomas

and analyzee the relationship between their expressions and prognosis. Methods Immunohistochemistry SP methods were applied to detect the expressions of MCT1 and CD147 in 28 cases of low grade gliomas and 32 cases high grade gliomas. Their expression level and correlation were analyzed statistically. Prospective cohorts were set to acquire follow-up data. Kaplan-Meier curve and Cox multi-factor model were used to analyze patients’ prognosis. Results Both CD147 and MCT1 had strong expressions in human gliomas. The positive expression rate of MCT1 and CD147 （93.8% and 90.6%） and the strong positive expression rate (73.3% and 72.4%) in high grade gliomas were significantly enhanced compared with that of low grade gliomas (positive expression rate: 46.4% and 50%

strong positive expression rate: 30.8% and 35.7%

P0.01

P0.05) and their expression had positive correlation (r=0.671

P0.05). The Kaplan-Meier curve related with the expression of MCT1 and CD147 were statistically different（P=0.021 and P=0.001）

CD147 significantly interfered with patients’ prognosis in COX analysis（P=0.017）. Conclusion The expressions of CD147 and MCT1

especially CD147

are closely related to the malignant degree of gliomas. They may be useful reference factors to evaluate prognosis of human gliomas and potential targets for therapy.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

CD147/HAb18G monoclonal antibody suppresses glycolysis lactic acid metabolism in human glioma cells in vitro

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Association of 5-factor modified frailty index and controlling nutritional status score with overall survival in patients with unresectable hepatocellular carcinoma undergoing interventional therapy

Related Author

王晓澍

游潮

孙晓川

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰